IV trial - great results I have just had a chance to look at the...

IV trial - great results
I have just had a chance to look at the poster presentation of the IV results – how fantastic the results are.
Data was reported on six patients – I expect these would be the hardest patients possible to test. They have all been treated with other drug regimens and have failed to respond and would be end stage patients wanting to try any new drug.
These are first ever in man IV results – purely a safety trial. Of the six patients FOUR have significant tumour reductions. One patient left the trial (this would be expected with such late stage patients). That is amazing. Imagine what will happen in the third cohort with a dose that I think is 100 times greater than cohort 2.
And there were no safety issues. You don’t get much better than this.
While early days this looks like CAVATAK will work with IV delivery – the range of cancers we might be able to treat will be huge.
This adds immense value to the stock and yes there is more good news.
It appears CAVATAK enhances the immune response and will likely make the check point inhibitors work more effectively. Once cohort 3 is complete the trial will progress to a combination Cavatak and checkpoint inhibitor trial. Imagine how big this will be if that shows positive results and there is nothing I can see that shows it will not work.
The mantra from all pharma companies is combination treatment.
When people understand what has been presented the share price should rocket